Shots:

• The (AVEIR DR i2i) IDE study evaluates AVEIR DR leadless pacemakers in 300 patients through 3mos. post-implant across 55 centers in the US, Canada & EU
• The study met its 3 prespecified 1EPs i.e., 98.3% implant success rate & the study also achieved the safety EPs, ≥97% of patients had successful AV synchrony which means that the upper and lower chambers were beating normally despite different types of underlying slow heart rhythms
• Aveir DR could offer new benefits for those with slower-than-normal heart rhythms & the results were presented at HRS 2023 & published in the NEJM. Aveir DR delivers electrical impulses to the heart muscle via thin, insulated wires, known as cardiac leads that restore the normal heart rhythm

Ref: Abbott | Image: Abbott

Related News:- Abbott’s Assert-IQ Insertable Cardiac Monitor Receives the US FDA’s Clearance for Irregular Heartbeats